The diagnostic potential of novel biomarkers of hypertension in men

Angelika E Charkiewicz; Marzena Garley; Wioletta Ratajczak-Wrona; Ewa Jabłońska; Wojciech Miltyk; Joanna Motyka; Wioleta J Omeljaniuk

doi:10.5114/aoms/153500

The diagnostic potential of novel biomarkers of hypertension in men

Arch Med Sci. 2022 Nov 7;18(6):1666-1671. doi: 10.5114/aoms/153500. eCollection 2022.

Authors

Angelika E Charkiewicz¹, Marzena Garley², Wioletta Ratajczak-Wrona², Ewa Jabłońska², Wojciech Miltyk³, Joanna Motyka⁴, Wioleta J Omeljaniuk³

Affiliations

¹ Department of Public Health Medical, University of Bialystok, Bialystok, Poland.
² Department of Immunology, Medical University of Bialystok, Bialystok, Poland.
³ Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, Bialystok, Poland.
⁴ Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, Bialystok, Poland.

Abstract

Introduction: The present study aimed to evaluate the diagnostic usefulness of selected novel parameters as biomarkers of hypertension: miR-145-5p, miR-1-3p, miR-423-5p, PCSK9, MyBPC3, NOX1, and CYBb, and NCF2, DNase 1, anti-MPO and anti-PR3 antibodies.

Methods: We present the data of men with normal blood pressure, diagnosed hypertension, confirmed hypertension, and hypertension and coexisting coronary artery disease.

Results: Elevated levels of miR-145-5p, miR-1-3p, and miR-423-5p and high levels of PCSK9, MyBPC3, and DNase 1 were observed in all groups of hypertensive men. We showed decreased levels of NOX1 and CYBb, and an elevated level of NCF2.

Conclusions: PCSK9 shows the greatest potential as an early biomarker of screening-detected hypertension.

Keywords: biomarkers; hypertension; microRNA; neutrophil extracellular traps; neutrophils.